Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224642
Recommendations on the use of azole antifungals in hematology-oncology patients
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires the administration of some drugs in the azole group, which include voriconazole, posaconazole and isavuconazole, noted for their activity against these pathogens. One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematologic tumors, with serious complications. In this regard, acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporine A, dasatinib, duvelisib, gilteritinib, glasdegib, ibrutinib, imatinib, nilotinib, ponatinib, prednisone, ruxolitinib, tacrolimus, all-transretinoic acid, arsenic trioxide, venetoclax, or any of the vinca alkaloids, are very clear examples of risk, in some cases because their clearance is reduced and in others because of increased risk of QTc prolongation, which is particularly evident when the drug of choice is voriconazole or posaconazole.
Matèries (anglès)
Citació
Citació
RAMÓN AZANZA, José, MENSA, José, BARBERÁN, José, VÁZQUEZ, Lourdes, PÉREZ DE OTEYZA, Jaime, KWON, Mi, YÁÑEZ, Lucrecia, AGUADO, José maría, CUBILLO GRACIAN, Antonio, SOLANO, Carlos, RUIZ CAMPS, Isabel, FORTÚN, Jesús, SALAVERT LLETÍ, Miguel, GUDIOL, Carlota, OLAVE RUBIO, Teresa, GARCIA VIDAL, Carolina, ROVIRA TARRATS, Montserrat, SUÁREZ-LLEDÓ GRANDE, María, GONZÁLEZ SIERRA, Pedro, DUEÑAS GUTIÉRREZ, Carlos. Recommendations on the use of azole antifungals in hematology-oncology patients. _Revista Española de Quimioterapia_. 2023. Vol. 36, núm. 3, pàgs. 236-258. [consulta: 21 de gener de 2026]. ISSN: 0214-3429. [Disponible a: https://hdl.handle.net/2445/224642]